Arete Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

Arete Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,900	Closed	-$233K	–	375
2019 Q4	$233K	Sell	9,900 -400	-4%	-$8.85K	0.04%	345
2019 Q3	$191K	Hold	10,300	–	–	0.04%	382
2019 Q2	$191K	Buy	+10,300	New	+$206K	0.04%	373

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arete Wealth Advisors's HRTX Position: Q1 2020 in Review

Arete Wealth Advisors sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 9,900 shares — an estimated $233K sold.

Arete Wealth Advisors first reported a position in HRTX in Q2 2019 and held it in 3 quarters. The position peaked at $233K in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Arete Wealth Advisors reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Arete Wealth Advisors sold 9,900 Heron Therapeutics shares in Q1 2020, an estimated $233K.
Arete Wealth Advisors first reported a position in Heron Therapeutics in Q2 2019 and held it in 3 quarters.
Arete Wealth Advisors's Heron Therapeutics position peaked at $233K in Q4 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Arete Wealth Advisors's 13F filing for Q1 2020, filed 14 May 2020.